| Megace Dosages & Strengths | ||||
|---|---|---|---|---|
| Strength | Format | Route | Strength | Class |
| Megace 20 mg | tablet | oral | 1.0 each | OTC |
| Megace 40 mg | tablet | oral | 1.0 each | OTC |
| Megace 40 mg/mL | suspension | oral | 1.0 milliliter(s) | OTC |
Posted by appliancemd over 2 years ago
pulmonary embolism
Posted by dragonfly74 over 4 years ago
I got a blood clot that almost killed me if anyone wants to talk about it. It also double the size of a uterine fibroid tumo...
GTXI: Additional Positive Data from Ph III Trial of Tremifene ... - Trading Markets (press release)
... in the Phase III ADT clinical trial experiencing six or more hot flashes per day at baseline and not being treated with megestrol acetate (Megace(R)), ...
Mon Mar 03 08:27:12 -0500 2008
GTXI: Additional Positive Data from Ph III Trial of Tremifene ... - Trading Markets (press release)
... in the Phase III ADT clinical trial experiencing six or more hot flashes per day at baseline and not being treated with megestrol acetate (Megace(R)), ...
Mon Mar 03 08:27:12 -0500 2008
GTx Announces Additional Top Line Phase III Data Demonstrating ... - Business Wire (press release)
... ADT clinical trial experiencing six or more hot flashes per day at baseline and not being treated with megestrol acetate (Megace ® ), toremifene citrate ...
Mon Mar 03 06:02:13 -0500 2008
megestrol acetate - The acetate salt form of megestrol, a synthetic derivative of the naturally occurring female sex hormone progesterone with anti-estrogenic activity and used in breast cancer treatment. Mimicking the action of progesterone, megestrol acetate binds to and activates nuclear progesterone receptors in the reproductive system, and causes the ligand-receptor complex to be translocated to the nucleus where it binds to and promotes expression of target genes. This leads to an alteration in protein synthesis, which modulates cell growth of reproductive tissues. Due to the negative feedback mechanism seen with progesterone, megestrol also blocks luteinizing hormone (LH) release from the pituitary gland, thereby leading to an inhibition of ovulation and an alteration in the cervical mucus and endometrium. Furthermore, without stimulation of LH, estrogen release from the ovaries is stopped, hence impedes the growth of estrogen-sensitive tumor cells.